

Chaochen Wang

Principal Scientist

✉ chaochen.wang1@alumni.lshtm.ac.uk 🌐 wangcc.me | Updated: July 21, 2025

EDUCATION

London School of Hygiene & Tropical Medicine , MSc of Medical Statistics, Distinction Degree	2018.9
Nagoya University Graduate School of Medicine , PhD in Public Health	2016.3
Nagoya University Graduate School of Medicine , Master of Medical Science in Epidemiology	2013.3
Shanghai Jiaotong University , B.S. Nutrition Science	2010.7

AWARDS & SCHOLARSHIPS

Outstanding Graduates of Shanghai Jiaotong University	2010
Recipient of Ajinomoto Scholarship for outstanding students from overseas	2011-2012
Young Investigator's Award , The 48th Annual Meeting of the Japanese Society of Cardiovascular Disease Prevention, Tokyo	2012
Recipient of scholarship from Otsuka Toshimi Scholarship Foundation	2013-2014
Best Reviewer of Journal of Epidemiology	2021.1.28
Lilly Japan 2024Q2 President Award winner	2024
Lilly Japan Innovator Award	2024

- Innovative machine learning approach in Japan real world effectiveness study for RA patients.
- Using SNS data to reveal Atopic dermatitis patients' unmet needs for future personalized treatment strategy
- Promoting innovative readiness from the early phase of development of Lp(a): evidence from large-scale epidemiological study in Japan.

LANGUAGES

- Chinese Mandarin: Native Speaker
- Chinese Hokkien: Native Speaker
- English: Fluent (IELTS overall: 8; L 8.5, R 8.5, W 7, S 7) - 2017.1.7
- Japanese: Advanced (Japanese Language Proficiency Level 1)

CAREER HISTORY

Japan Value, Evidence and Outcomes (VEO), Japan Drug Development and Medical Affairs (JDD&MA), Eli Lilly and Company Japan K.K.

Principal Scientist 2024.3-Present

Japan Value, Evidence and Outcomes (VEO), Japan Drug Development and Medical Affairs (JDD&MA), Eli Lilly and Company Japan K.K.

Senior Scientist 2021.10–2024.3

Responsibility: Real world evidence (RWE) planning and generation

- Develops and oversees local RWE strategy for Lilly's products in Japan in immunology, CVD and oncology area
- Answering data queries from internal clients (marketing/pricing/clinical development/medical affairs etc.) using commercially available databases: Medical Data Vision, JMDC Claims database, etc.

- Lead in proposing, designing, and execution of observational researches generate RWE to support compounds from early clinical development throughout the whole life cycle.
- Key member of Lilly Japan's internal real world related working groups of
 - Integrated data platform for diverse RWD/E utilization
 - Scientific study design
 - Real-world data analytics
- Attended the VEO International Meeting in the UK (2024/04/14 - 2024/04/21) on behalf of Eli Lilly Japan VEO scientists, exchanging knowledge with Chinese and European colleagues and presenting our experiences on research collaborations with Public Interest Association and academic institutions

Department of Public Health, Aichi Medical University School of Medicine:

Assistant Professor

2015.4–2021.9

Responsibility: teaching and research

- Working closely with the professors and other colleagues mainly in epidemiology of gastroenterological cancer
- Responsible for statistical consulting from medical doctors in the university hospital
- Responsible for education to undergraduate medical students on statistical methods used in medical researches
- Cooperating with medical doctors in hospital university on projects studying locomotive syndrome

Projects:

- Data analysis using large scale cohort studies such as the Japan Collaborative Cohort Study, literature meta-analysis, the UK National Diet and Nutrition Survey Rolling Program data, and data provided by doctors in Aichi Medical University hospital
- All projects and publications were conducted under Linux environment such as Ubuntu OS with R, STATA, and/or Python language
- Presented in the World Congress of Epidemiology in Alaska (2014) as well as in Saitama (2017) as poster presentations
- Research on the day-time patterns of carbohydrate intake using the UK national Diet and Nutrition Survey data was accepted as oral presentation in the 13th European Nutrition Conference in Dublin, Ireland 2019

Nagoya University Graduate School of Medicine - Department of Public Health and Health Systems

Visiting Faculty

Responsibility:

- Provide lectures/seminars (topics include advanced statistical methodology such as Causal Inference) to graduate students in the Department of Public Health and Health Systems

Clinical Study Support:

Part-time Researcher (8h/w)

2018.10–2021.6

Responsibility: statistical analysis, training of the analysis team

- Experience in producing statistical analysis plan (SAP) for clinical and observational studies; conducted detailed comparisons and results calculation on cancer survival from hospital clients; performed database analyses through commercial medical databases such as Medical Database Vision.
- Organizing statistical study seminars to train the team members and learn the latest statistical knowledge and skills for on-going and future study projects

PUBLICATIONS:

(while in Eli Lilly):

- *Wang, C., Aranishi, T., Reed, C., Anderson, P., Austin, J., Davis, V. A., Quinones, E., & Piercy, J. (2022). Impact of Patient and Physician Disconnect on Satisfaction with Treatment for Atopic Dermatitis in Japan. *Dermatology and Therapy*. <https://doi.org/10.1007/s13555-022-00866-z>
- Maruyama, D., *Wang, C., Y. Tanizawa, Z. Cai, Y. Huang, M. Tajimi and S. Kusumoto (2023). "Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study." *J Clin Exp Hematop* 63(4): 219-229.
- *Wang, C., T. Ishizuka, M. Tanaka, K. Matsuo, H. Knight, N. Harvey, L. Gillespie-Akar and T. H. Gibble (2023). "Bowel Urgency in Patients with Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Real-World Survey in Japan." *Adv Ther*.
- *Wang, C., H. Torisu-Itakura, T. Hanada, T. Matsuo, Z. Cai, S. Osaga and T. Aranishi (2023). "Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study." *Journal of Dermatological Treatment* 34(1).
- Kagawa, Y., *Wang, C., Y. Piao, L. Jin, Y. Tanizawa, Z. Cai and Y. Sunakawa (2024). "Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study." *Target Oncol*.
- Otsuka, A., *Wang, C., H. Torisu-Itakura, T. Matsuo, Y. Isaka, P. Anderson, J. Piercy, J. Austin, S. Marwaha and A. Tanaka (2024). "Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan." *Int J Dermatol*.
- Yuda, J., *Wang, C., T. Terasawa, M. Tajimi, S. Osaga, M. Miura, S. Takaoka and Y. Tanizawa (2024). "Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan." *Int J Clin Oncol*.
- Nishino, K., *Wang, C., S. Mizuno, N. Sekine, Y. Tanizawa, Z. Cai and K. Nakamura (2024). "Real-world Evidence of Skin Disorder-related Events Management in Patients with Lung Cancer Prescribed the RELAY Regimen (Erlotinib Plus Ramucirumab) - A Retrospective Observational Study Using A Health Insurance Claims Database in Japan [Article in Japanese]." *J. New Rem. & Clin.* 73: 7.
- Lipoprotein(a) levels and the risk of coronary heart disease and stroke: the Suita Study. *Journal of Atherosclerosis and Thrombosis*. 2025 (accepted for publication, this is a collaborative study between Lilly and National Cerebral and Cardiovascular Center)

More Publications before joining Eli Lilly can be found from [ORCID 0000-0001-5533-1497](https://orcid.org/0000-0001-5533-1497)